Articles tagged with Megakaryocytes
Interferon-alpha treatment depletes mutant blood stem cells and induces production of infection-fighting white blood cells, potentially benefiting patients with myeloproliferative neoplasms. The study's findings provide new strategies for managing these blood cancers.
Researchers at Boston Children's Hospital identified a new target responsible for bone marrow scarring in myelofibrosis, a type of blood cancer. Combining traditional therapy with drugs blocking scar formation may improve treatment outcomes. The study found that inhibiting freecycling activity with drugs like hydroxychloroquine can red...
Researchers at UCSF have discovered that human lung tissue contains hematopoietic stem cells (HSCs) capable of producing red blood cells, platelets, and immune cells. The finding suggests the lungs could be a potent source for life-saving stem cell transplants, particularly for patients with leukemia.
A Stanford Medicine-led study has discovered a molecular signature in the blood that can predict how long an individual's vaccine immunity will last. The signature, found in platelet RNA molecules, is associated with megakaryocyte activation in the bone marrow and can forecast longer-lasting antibody responses to various vaccines.
Researchers identified a molecular signature in blood that predicts vaccine response durability, pointing to megakaryocytes as key players. The discovery may lead to personalized vaccines and better understanding of vaccine science.
Researchers found that megakaryocyte conditioned media from younger mice was more effective at promoting blood vessel growth and improving healing. The study provides a potential approach for developing new therapies to speed up fracture recovery in older individuals, reducing pain and improving mobility.
Researchers at LMU University Hospital have discovered that plasmacytoid dendritic cells control the formation of new megakaryocytes from progenitor cells in bone marrow, regulating platelet production and potentially treating Covid-19. The study found pDCs precisely adjust MK quantities to meet bodily needs.
A new research group led by Zoltan Nagy is working to understand megakaryocyte development and maturation. The team will use single-cell RNA sequencing to identify key factors controlling platelet production, with the goal of improving platelet counts for transfusions.
Researchers at UVA Health System have made a groundbreaking discovery that could boost platelet production on demand to alleviate blood shortages. The finding offers hope for patients with thrombocytopenia and those receiving cord-blood transplants.
A study published in JAMA Neurology suggests that large bone marrow cells called megakaryocytes may be responsible for the lingering aftereffects of severe COVID-19 cases, including brain fog. The researchers found evidence of megakaryocytes in the brains of patients who died from COVID-19 and believe they may reduce blood flow to the ...
Researchers inhibited a specific protein to decrease megakaryocyte numbers in an experimental model, showing promise for treating myeloproliferative neoplasms. The study's findings suggest a potential complementary or alternative therapy for this debilitating disease.
A team of researchers led by University of Delaware Professor Velia M. Fowler has made a groundbreaking discovery about MYH9-related disorders, a condition affecting 1 in 25,000 people. The study found that mutations in the MYH9 gene disrupt platelet formation and movement, leading to unstable clots and various health issues.
Researchers discovered that megakaryocytes influence the migration of hematopoietic stem cells and neutrophils in the bone marrow. The study found that large megakaryocytes act as passive obstacles, reducing neutrophil mobility. This new understanding highlights the importance of biomechanical properties in regulating cell motility.
Researchers in Japan have developed a new method to produce functional platelets from human induced pluripotent stem cells using turbulence, enabling clinical-scale production. The discovery has the potential to address the shortage of platelets and reduce reliance on blood donations.
Researchers used intravital correlative light-electron microscopy to visualize platelet production in vivo. They found that megakaryocytes form large protrusions rather than extruding fine proplatelet extensions, revising the understanding of fundamental biology of platelet formation.
Researchers at UVA School of Medicine have identified a 'master switch' that controls platelet production in the bone marrow, offering new hope for treating platelet shortages and neonatal thrombocytopenia. The discovery may lead to the development of new treatments using existing compounds with improved efficacy and reduced side effects.
Researchers found that mouse lungs produce over half of the body's platelets and contain a pool of stem cells capable of restoring blood production. This discovery suggests the lungs may also play a key role in human blood formation, with implications for treating diseases like thrombocytopenia.
Researchers at CNIO have discovered a new way to produce platelets artificially, reprogramming megakaryocytes to increase in size. This breakthrough could lead to the development of new treatments for thrombocytopenia and cancer by targeting specific proteins involved in cell growth.
Scientists at the Stowers Institute discovered that megakaryocytes, a type of 'mega' cell in bone marrow, regulate stem cells to produce platelets and other blood cells. This finding could lead to new treatments for patients recovering from chemotherapy or organ transplantation.
Melbourne researchers solved a puzzle on how an essential hormone stimulates platelet production. They found that bone marrow cells can become overstimulated and produce too many platelets, leading to blood diseases such as essential thrombocythemia.
Researchers have found a way to create platelets without donated blood, potentially solving supply shortages and ensuring treatments for all who need them. The new method involves deriving functional platelets from human induced pluripotent stem cells, offering an alternative to traditional blood donations.
Researchers used iPS cells from a CAMT patient to study the disease, finding that thrombopoietin receptor signaling is crucial for megakaryocyte and erythrocyte production. Compensatory transduction of receptors normalized these processes, highlighting the potential for thrombopoietin-like drugs to treat anemia.
Yale researchers found that megakaryocytes grow 10-15 times larger than other blood cells through endomitosis, but a malfunction in this process may lead to leukemia. The discovery reveals the formation of functional platelets and provides clues about what may go awry to transform normal megakaryocytes into malignant leukemia cells.
Scientists at the Walter and Eliza Hall Institute have identified that pro-survival Bcl-2 family proteins are essential for keeping megakaryocytes alive to produce platelets. Chemotherapy kills megakaryocytes by activating 'pro-death' Bcl-2 proteins, leading to a drop in platelet numbers.
Researchers at the University of Pennsylvania have discovered that a single drug can induce bone marrow cells to quadruple platelet production. The study found that inhibiting myosin-II with the drug belebbistatin increases megakaryocyte growth, allowing them to produce more platelets in a soft environment.
Scientists have identified a potential new method for replenishing platelet cells, which could treat individuals with low platelet counts. The approach involves infusing mature megakaryocytes into mice, producing functional platelets of normal size and function.